Case Reports in Oncology最新文献

{"title":"Pulmonary Nocardiosis in a Non-Small Cell Lung Cancer Patient Being Treated for Pembrolizumab-Associated Pneumonitis.","authors":"Liam Quartermain, C Arianne Buchan, Elaine Kilabuk, Paul Wheatley-Price","doi":"10.1159/000541694","DOIUrl":"https://doi.org/10.1159/000541694","url":null,"abstract":"<p><strong>Introduction: </strong>Immune-check-point inhibitors (ICIs) are established in the treatment of many malignancies. Many immune-related adverse events (irAEs) are well described; however, there is less information about opportunistic infections in cancer patients receiving ICIs.</p><p><strong>Case presentation: </strong>We describe the case of a 62-year-old woman with non-small cell lung cancer, who relapsed after surgical resection and chemotherapy. She received 13 months of pembrolizumab, achieving stable disease, before presenting with suspected pneumonitis 2 weeks prior to departure for an international vacation. She was treated with high-dose corticosteroids and, shortly thereafter, developed severe nocardiosis, requiring venovenous extracorporeal membrane oxygenation and lengthy hospitalization.</p><p><strong>Conclusion: </strong>To our knowledge, this represents the second known case of pulmonary nocardiosis in a patient on pembrolizumab. Moreover, this is a rarely reported instance of opportunistic bacterial infection following steroid treatment for ICI pneumonitis. This case report emphasizes the risk of bacterial infection associated with ICI pneumonitis, both due to the difficulty of excluding underlying infection at presentation, and the immunosuppression caused by irAE treatment. As such, we suggest that clinicians maintain a high suspicion for potential infection in ICI pneumonitis, and strongly consider initiating infectious workup with regular follow-ups for monitoring. Prophylactic antibiotics could be considered when such monitoring is not possible.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1222-1228"},"PeriodicalIF":0.7,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11501102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142495754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appearances Can Be Deceiving: A Case Report of Asymptomatic Appendiceal Goblet Cell Adenocarcinoma Presenting as an Ovarian Tumor.","authors":"Hiroko Fukasawa, Rei Gou, Kota Tanaka, Yuri Tada, Hikaru Tagaya, Shinji Furuya, Naoki Oishi, Akihiko Hashi, Osamu Yoshino","doi":"10.1159/000541626","DOIUrl":"https://doi.org/10.1159/000541626","url":null,"abstract":"<p><strong>Introduction: </strong>Goblet cell adenocarcinoma (GCA) of the appendix is an uncommon type of cancer that includes both epithelial and neuroendocrine features, with goblet cells present. These tumors have traditionally been viewed as one of the more aggressive forms of appendiceal cancer, frequently being diagnosed at a metastatic stage. For patients with stage III-IV disease, the 5-year overall survival rate ranges from 14% to 22%. Due to limited data, the diagnosis and management of GCA are challenging.</p><p><strong>Case presentation: </strong>We present the case of a 55-year-old female who presented with elevated serum carcinoembryonic antigen levels and a left ovarian tumor. Preoperative imaging indicated a normal appendix. During surgery for suspected ovarian carcinoma, frozen section analysis revealed mucinous adenocarcinoma of the ovary, but distinguishing between primary and metastatic lesions was challenging. Meticulous exploration revealed a firm and thickened appendix, prompting appendectomy and subsequent diagnosis of appendiceal GCA with ovarian metastasis.</p><p><strong>Conclusion: </strong>Pathologies of the appendix, like GCA, can mimic ovarian tumors despite a normal-looking appendix, complicating diagnosis. Through this case, we underscored the need for careful intraoperative examination of the appendix in patients with mucinous ovarian neoplasms to avoid misdiagnosis and ensure appropriate treatment.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1214-1221"},"PeriodicalIF":0.7,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spontaneous Regression of an Inflammatory Myofibroblastic Tumor: A Case Report and a Review of the Literature.","authors":"Bianca Medici, Eugenia Caffari, Massimiliano Salati, Andrea Spallanzani, Ingrid Garajova, Federico Piacentini, Massimo Dominici, Fabio Gelsomino","doi":"10.1159/000541337","DOIUrl":"https://doi.org/10.1159/000541337","url":null,"abstract":"<p><strong>Introduction: </strong>Spontaneous tumor regression is the volumetric reduction or complete disappearance of a primary tumor or metastatic sites (single or multiple) without the administration of treatments. This rare phenomenon occurs most commonly in certain types of neoplasms.</p><p><strong>Case presentation: </strong>In this manuscript, we describe a spontaneous tumor regression in an adult patient followed at the Modena Cancer Center and affected by retroperitoneal inflammatory myofibroblastic tumor, an ultra-rare subtype of sarcoma. Finally, we will provide a concise review of the literature and try to explain the mechanisms underlying the tumor regression described in the clinical case.</p><p><strong>Conclusion: </strong>The etiopathogenetic mechanisms for spontaneous tumor regression are not yet fully understood and likely involve a complex interplay among immunological mechanisms, growth factors, cytokines, and hormonal factors.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1208-1213"},"PeriodicalIF":0.7,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521496/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chromosomal Abnormalities as a Predisposition to Secondary Neurolymphomatosis in Patients with Diffuse Large B-Cell Lymphoma: A Report of Two Cases and a Literature Review.","authors":"Naoki Watanabe, Sakiko Harada, Shoko Sato, Yasutaka Fukuda, Yuina Tanaka, Kensuke Yanashima, Eriko Sato, Daisuke Taniguchi, Yuji Tomizawa, Nobutaka Hattori, Miki Ando","doi":"10.1159/000541552","DOIUrl":"https://doi.org/10.1159/000541552","url":null,"abstract":"<p><strong>Introduction: </strong>Neurolymphomatosis (NL) is a rare condition characterized by the infiltration of malignant lymphoma cells into the peripheral nervous system. The optimal treatment for NL remains unclear, and patients with secondary NL have a poor prognosis. Although early recognition of NL may contribute to successful treatment, the predictive factors for secondary NL are yet to be established.</p><p><strong>Case presentation: </strong>Here, we present our investigation on the predictive factors for secondary NL, and report two cases of secondary NL with a literature review. We analyzed chromosomal abnormalities in patients with secondary NL and found a common deletion of chromosome 10 and add(11)(p11). The chromosomal abnormalities might be a predictive factor for secondary NL; therefore, confirmation of chromosomal abnormalities can possibly give a hint for early detect of secondary NL. Prompt histopathological examination or imaging techniques can lead to early diagnosis of secondary NL in patients with diffuse large B-cell lymphoma (DLBCL).</p><p><strong>Conclusion: </strong>When neurological symptoms manifest in patients with DLBCL and there are chromosomal abnormalities, the possible development of secondary NL should be considered.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1201-1207"},"PeriodicalIF":0.7,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Case of CUP with Malignant Pleural Effusion: Overcoming Diagnostic and Therapeutic Hurdles with Chemotherapy.","authors":"Andika Putra, Amadisto Gerwindrawan, Eko Budiono, Bambang Purwanto Utomo, Naela Himayati Afifah, Auliya Suluk Brilliant Sumpono, Heru Pradjatmo, Ibnu Purwanto","doi":"10.1159/000540866","DOIUrl":"https://doi.org/10.1159/000540866","url":null,"abstract":"<p><strong>Introduction: </strong>Cancers of unknown primary (CUPs) present a diagnostic challenge as their origin is unidentified at diagnosis. Massive pleural effusion (MPE), indicative of lung metastasis in CUP, categorizes the condition into an unfavorable subset with a poor prognosis. Patients in this subset may exhibit a lower response to specific therapies.</p><p><strong>Case presentation: </strong>A 62-year-old woman presented with cough, severe dyspnea, and MPE in the left lung. Thoracocentesis was performed, extracting 1,200 mL of hemorrhagic fluid, followed by the placement of an indwelling pleural catheter. The cytological examination of the pleural effusion indicated an adenocarcinoma, with immunohistochemistry revealing positive CK7 and negative CK20, Napsin A, and TTF-1. Additionally, elevated levels of Ca-125 (1,605 U/mL) and Ca 15-3 (242 U/mL) raised suspicion of gynecological malignancy. Thorax and abdominal CT scans, breast and thyroid ultrasounds showed no signs of malignancy, leading to the diagnosis of CUP. The patient's performance status according to the Eastern Cooperative Oncology Group (ECOG) score was 4. Initial carboplatin 5 AUC and paclitaxel 175 mg/m² administration resulted in improvement in performance status with ECOG score of 1, alleviation of dyspnea, reduction in pleural effusion 1 week after chemotherapy, with minimal effusion observed at 3 weeks, and Ca-125 levels decreased to 33.6 U/mL thereafter.</p><p><strong>Discussion: </strong>Empiric chemotherapy using carboplatin and paclitaxel is a feasible option for managing CUP with MPE mimicking gynecological malignancies with elevated Ca-125 and Ca 15-3 markers; initiating chemotherapy in poor performance status patients is beneficial with proper clinical judgment.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1194-1200"},"PeriodicalIF":0.7,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521488/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durvalumab-Induced Immune Thrombocytopenia in Patients with Advanced Cholangiocarcinoma Undergoing Yttrium-90 Radioembolization.","authors":"Maaz Khan Afghan, Areeb Lutfi, Fatima Qadri, Sahrish Khan, Sana Javaid, Brian Michael Currie, Juan Pablo Rocca, Benjamin Samstein, Erika Hissong, Pashtoon Murtaza Kasi","doi":"10.1159/000541550","DOIUrl":"https://doi.org/10.1159/000541550","url":null,"abstract":"<p><strong>Introduction: </strong>Immune thrombocytopenia (ITP) secondary to durvalumab, a programmed cell death ligand 1 inhibitor, is a rare but clinically significant immune-related adverse event. Herein, we present 2 patients with cholangiocarcinoma who developed ITP immediately post-yttrium-90 radioembolization (Y90-RE) while on durvalumab-based systemic therapy. We hypothesize that given the timing, the immunotherapy and the radioembolization combination led to this event. It is not uncommon given the approval of immunotherapy and its role in locoregional therapies, that patients are treated with a combination of systemic immunotherapy and radioembolization or other forms of radiation, thus signifying the importance of potential complications.</p><p><strong>Case presentation: </strong>Two patients, a 67-year-old female and a 60-year-old man, with biopsy-proven advanced unresectable cholangiocarcinoma, received a combination of systemic therapy with durvalumab, gemcitabine, and cisplatin and subsequently Y90-RE. Both patients developed ITP following in the immediate post-Y90-RE period. All other causes of ITP were comprehensively ruled out and treatment for ITP was initiated in the form of high-dose steroid and intravenous immunoglobulins. Durvalumab was discontinued, and only gemcitabine/cisplatin-based chemotherapy was continued thereafter. Due to recurrence, one of the patients required longer courses of steroids as well as thrombopoietin receptor agonists.</p><p><strong>Conclusion: </strong>Immunotherapy in the form of durvalumab and now pembrolizumab alongside chemotherapy is an approved first-line standard of care. Furthermore, it is not uncommon for patients to receive Y90-RE to improve patient outcomes. This report highlights the development of ITP in 2 patients who received durvalumab alongside Y90-RE. Awareness of this as a potential immune-mediated event is important to allow for close monitoring of platelet counts and for early intervention/management when this occurs.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1183-1193"},"PeriodicalIF":0.7,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Surviving Twenty Years to Bone and Liver Metastatic Breast Cancer: A Case Reported by Treating Oncologists and the Patient Herself.","authors":"Maria Rosaria Valerio, Vittorio Gebbia, Dario Piazza, Giuseppina Campisi, Eleonora D'Agati, Monica Bazzano","doi":"10.1159/000541391","DOIUrl":"https://doi.org/10.1159/000541391","url":null,"abstract":"<p><strong>Introduction: </strong>Metastatic breast cancer (MBC) presents an enduring and significant challenge for affected women, requiring sustained commitment over the years.</p><p><strong>Case presentation: </strong>This paper presents a case of a woman affected by bone and visceral MBC with a very long 20-year survival, excellent quality of life, and high resilience. She is now 51 years old and underwent quadrantectomy for breast cancer in 2005, and in 2013, she developed a recurrence with bone and liver metastases. Despite the widespread stage of the disease with visceral compromise, the patient was treated with a multidisciplinary approach that included surgery, chemotherapy, radiotherapy, hormone therapy, bone target agents, metabolic radiotherapy, and ozone therapy for medication-related osteonecrosis of the jaw. Multidisciplinary management results in a complete clinical and metabolic response to treatment in a visceral metastatic setting.</p><p><strong>Conclusion: </strong>This report supports the possibility of achieving unusual survival outcomes in patients with MBC. This study also highlights the importance of resilience in breast cancer patients who continue to manage their disease and pursue treatment for over 2 decades. Understanding these resilience factors can improve clinical practice and support patients' long-term care.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1174-1182"},"PeriodicalIF":0.7,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Confronting Complexity: Stereotactic Body Radiation Therapy for Localized Lung Cancer with a Pacemaker.","authors":"Malak Chahid, Hanae El Gouach, Mohamed Reda Cherkaoui Jaouad, Meriem Damou, Mohammed Sqalli Houssaini, Fadila Kouhen","doi":"10.1159/000540262","DOIUrl":"https://doi.org/10.1159/000540262","url":null,"abstract":"<p><strong>Introduction: </strong>Lung cancer management in patients with pacemakers presents unique challenges. This report examines the utilization of stereotactic body radiation therapy (SBRT) in such a patient population.</p><p><strong>Case presentation: </strong>A 75-year-old former smoker with a dual-chamber pacemaker presented with inoperable lung adenocarcinoma. SBRT (48 Gy in 4 fractions) was chosen following multidisciplinary consultation and thorough pretreatment evaluation by a rhythmologist to assess pacemaker integrity. Continuous cardiac monitoring during SBRT detected no arrhythmias. Adjuvant therapy consisted of radiotherapy alone due to the patient's health status and limited evidence supporting chemotherapy in this context. At the 18-month follow-up, no cancer recurrence was observed, and regular device checks confirmed pacemaker integrity.</p><p><strong>Conclusion: </strong>This case demonstrates the successful management of inoperable lung adenocarcinoma with SBRT in a patient with a pacemaker. It underscores the significance of interdisciplinary cooperation and careful patient assessment to optimize treatment outcomes in this challenging clinical scenario.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1166-1173"},"PeriodicalIF":0.7,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521424/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammatory Breast Cancer and Transient Complete Radiographic Response to Chemoimmunotherapy: A Case Report.","authors":"Adina Amin, Sasis Sirikanjanapong, Amardeep Kalsi, Evelyn Taiwo","doi":"10.1159/000541314","DOIUrl":"https://doi.org/10.1159/000541314","url":null,"abstract":"<p><strong>Introduction: </strong>Inflammatory breast cancer is a rare and aggressive subtype, with high breast cancer mortality. Compared to noninflammatory breast cancer, even after treatment and response to standard-of-care breast cancer chemotherapy, it has a high propensity for lymph node involvement, high rates of distant metastasis, and shorter survival. The immune checkpoint inhibitor, pembrolizumab, in combination with chemotherapy is now approved for early triple negative breast cancer (TNBC) and for advanced disease if positive for the programmed cell death ligand 1 protein (PD-L1). The response and survival of metastatic inflammatory TNBC to immunotherapy is largely unreported and we present a case of a young woman with metastatic triple negative inflammatory breast cancer, treated with pembrolizumab, carboplatin, and paclitaxel.</p><p><strong>Case presentation: </strong>A 46-year-old female presented with de novo metastatic inflammatory TNBC with metastasis to lymph nodes, lung, and bones. She was treated with pembrolizumab, carboplatin, and paclitaxel leading to rapid and complete radiographic response. The response was however short lived, and the patient presented with diffuse disease progression in the lungs with pleural effusions, causing death from respiratory distress.</p><p><strong>Conclusion: </strong>Treatment for metastatic triple negative inflammatory breast cancer mirrors treatment of metastatic TNBC. In PD-L1 positive disease, treatment with chemotherapy and pembrolizumab is first line and in this case led to robust but short-lived response. Inflammatory breast cancer remains a poorly understood breast cancer subtype, and even in the presence of good treatment response, prognosis and survival remain poor. Further studies are warranted to better understand and treat the disease.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1157-1165"},"PeriodicalIF":0.7,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Intravenous and Oral Topotecan in Small-Cell Lung Cancer Truly Equal? A Case Report.","authors":"Davien Deraedt, Saartje Verfaillie, Jokke Wynants, Kristof Cuppens","doi":"10.1159/000540861","DOIUrl":"https://doi.org/10.1159/000540861","url":null,"abstract":"<p><strong>Introduction: </strong>Treatment with topotecan is standard-of-care therapy for relapsed small-cell lung cancer (SCLC). Both oral and intravenous administrations of topotecan have been extensively researched and are found to be equally effective with less adverse events in the oral group.</p><p><strong>Case presentation: </strong>We report a case of a patient with SCLC, who had previously received oral topotecan, with radiological stable disease with no changes in tumor or metastasis diameter size after two administrations. Subsequently, this patient received intravenous topotecan instead of oral due to supply difficulties. After one administration of intravenous topotecan, we saw significant disease regression.</p><p><strong>Conclusion: </strong>This is to our knowledge the first reported case of better response of intravenous topotecan than oral topotecan. Multiple extrinsic (e.g., food, medication) factors were investigated but could not deliver an explanation.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"17 1","pages":"1140-1145"},"PeriodicalIF":0.7,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11521484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142543961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}